Hassan Fred — SEC insider filings

SEC reporting owner CIK 1110744. 33 insider filings on record with FilingPulse; latest filed 2026-11-04.

Transaction summary — filings shown

Covers all 33 filings on record, filed 2021-03-16 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
PRECIGEN, INC. (PGEN)Director121 leg · 570,345 sh · $998,104—30
BridgeBio Pharma, Inc. (BBIO)Director71 leg · 19,300 sh · $273,390—8
Prometheus Biosciences, Inc. (RXDX)Director5——8
Cocrystal Pharma, Inc. (COCP)Director4——5
EyePoint, Inc. (EYPT)Director3——3
RECURSION PHARMACEUTICALS, INC. (RXRX)Director2——1

Insider filings — Hassan Fred

FiledFormIssuerReported transactionsSource
2026-11-043RECURSION PHARMACEUTICALS, INC. (RXRX)Holdings only — no transactions reportedEDGAR
2026-11-044RECURSION PHARMACEUTICALS, INC. (RXRX)Grant/award (A): 156,658 @ $0EDGAR
2026-06-244BridgeBio Pharma, Inc. (BBIO)Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0EDGAR
2026-03-164PRECIGEN, INC. (PGEN)Option exercise (M): 71,839 · Option exercise (M): 71,839 (derivative) @ $0EDGAR
2026-03-124PRECIGEN, INC. (PGEN)Grant/award (A): 17,948 @ $3.51 · Grant/award (A): 35,612 (derivative) @ $0 · Grant/award (A): 41,073 (derivative) @ $0EDGAR
2026-01-134Cocrystal Pharma, Inc. (COCP)Grant/award (A): 16,410 (derivative) @ $0EDGAR
2026-01-064EyePoint, Inc. (EYPT)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2025-10-304Cocrystal Pharma, Inc. (COCP)Grant/award (A): 359,713 @ $1.39 · Grant/award (A): 719,426 (derivative) @ $1.39EDGAR
2025-06-244BridgeBio Pharma, Inc. (BBIO)Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0EDGAR
2025-03-174PRECIGEN, INC. (PGEN)Grant/award (A): 36,206 @ $1.74 · Option exercise (M): 87,412 · Grant/award (A): 71,839 (derivative) @ $0 · Option exercise (M): 87,412 (derivative) @ $0 · Grant/award (A): 83,517 (derivative) @ $0EDGAR
2025-01-074EyePoint Pharmaceuticals, Inc. (EYPT)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2024-10-114Cocrystal Pharma, Inc. (COCP)Grant/award (A): 8,067EDGAR
2024-09-054EyePoint Pharmaceuticals, Inc. (EYPT)Grant/award (A): 60,000 (derivative) @ $0EDGAR
2024-06-254BridgeBio Pharma, Inc. (BBIO)Grant/award (A): 26,014 (derivative) @ $0EDGAR
2024-03-184PRECIGEN, INC. (PGEN)Grant/award (A): 44,055 @ $1.43 · Grant/award (A): 87,412 (derivative) @ $0 · Grant/award (A): 101,626 (derivative) @ $0EDGAR
2024-03-124PRECIGEN, INC. (PGEN)Option exercise (M): 106,837 · Option exercise (M): 106,837 (derivative) @ $0EDGAR
2023-08-164PRECIGEN, INC. (PGEN)Purchase (P): 570,345 @ $1.75EDGAR
2023-07-204Cocrystal Pharma, Inc. (COCP)Grant/award (A): 7,333 (derivative) @ $0EDGAR
2023-06-234BridgeBio Pharma, Inc. (BBIO)Grant/award (A): 51,501 (derivative) @ $0EDGAR
2023-06-164Prometheus Biosciences, Inc. (RXDX)Disposition to issuer (D): 2,123 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 541 (derivative) · Disposition to issuer (D): 21,013 (derivative)EDGAR
2023-05-194Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 2,123 @ $0EDGAR
2023-03-134PRECIGEN, INC. (PGEN)Grant/award (A): 48,290 @ $1.17 · Grant/award (A): 106,837 (derivative) @ $0 · Grant/award (A): 125,489 (derivative) @ $0EDGAR
2023-02-244PRECIGEN, INC. (PGEN)Option exercise (M): 61,576 · Option exercise (M): 61,576 (derivative) @ $0EDGAR
2022-06-244BridgeBio Pharma, Inc. (BBIO)Grant/award (A): 104,921 (derivative) @ $0EDGAR
2022-05-204Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 21,013 (derivative) @ $0EDGAR
2022-03-294PRECIGEN, INC. (PGEN)Option exercise (M): 16,212 · Option exercise (M): 16,212 (derivative) @ $0EDGAR
2022-02-244PRECIGEN, INC. (PGEN)Grant/award (A): 27,832 @ $2.03 · Grant/award (A): 61,576 (derivative) @ $0 · Grant/award (A): 83,189 (derivative) @ $0EDGAR
2022-01-034BridgeBio Pharma, Inc. (BBIO)Purchase (P): 19,300 @ $14.17EDGAR
2021-11-164Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 541 (derivative) @ $0EDGAR
2021-08-264BridgeBio Pharma, Inc. (BBIO)Grant/award (A): 49,869 (derivative) @ $0EDGAR
2021-05-174Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2021-03-294PRECIGEN, INC. (PGEN)Grant/award (A): 7,328 @ $7.71 · Grant/award (A): 16,212 (derivative) @ $0 · Grant/award (A): 22,107 (derivative) @ $0EDGAR
2021-03-164PRECIGEN, INC. (PGEN)Option exercise (M): 62,189 · Option exercise (M): 62,189 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-03-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1110744 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs